BOEHRINGER-INGELHEIM
It takes years of diligent training as well as a trusting relationship between horse and rider to reach their full potential as a team. That’s why a tendon or ligament injury can be devastating for horse owners, riders and trainers. For equine athletes, the diagnosis may mean many months of treatment and rehabilitation with an unknown outcome, and potential for long term impact on their ability to perform.
Boehringer Ingelheim has now received approval in Europe for RenuTend™, the first product licensed to improve healing of tendon and suspensory ligament injuries in horses. RenuTend™ is administered by intralesional injection and complements Boehringer Ingelheim’s other equine stem cell product Arti-Cell® FORTE, which is authorised to treat mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.
“We are delighted to add RenuTend™ to our portfolio of stem cell products for horses, offering veterinarians a new therapeutic option for treating tendon and suspensory ligament injuries. This product demonstrates the company's commitment to bringing innovation to improve the lives of horses and the people who love them,” comments Liz Barrett, Head of Global Strategic Marketing, Equine at Boehringer Ingelheim. “RenuTend™ will allow more riders, owners and trainers to reimagine the dreams a tendon injury jeopardizes, by optimizing the possibilities for their horse to return to work with reduced potential for reinjury.”
Tendon and ligament lesions don’t always heal properly, as scar tissue can be less elastic than healthy tissue, and reinjury rates can be up to 80 percent. This can mean the end of a career for many horses. RenuTend™ is a targeted stem cell treatment with proven efficacy and repeatable results. It improves the quality of tendon healing by promoting parallel alignment of the right type of fibres and decreases the amount of scar tissue formed.
RenuTend™ will be available across the European Union. The approval for Great Britain is still pending.
Please click on the link for ‘Notes to Editors’ and ‘References’:
https://www.boehringer-ingelheim.com/animal-health/companion-animals/horses/stem-cell-therapy-tendon-and-ligament-injuries-horses
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005467/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Maxion Announces Strategic Actions to Serve Growing Demand for Light Vehicle Aluminum Wheels in South America3.11.2025 23:38:00 CET | Press release
Includes Joint Venture through Polimetal to Increase Capacity in Argentina Iochpe-Maxion (B3: MYPK3) through its wheels business, Maxion Wheels, announced the strategic expansion of its light vehicle aluminum wheels business in South America with the redeployment of existing global assets to Brazil, and the acquisition of a 50.1% shareholding in Polimetal, a leading producer of aluminum wheels in Argentina. “Passenger car sales continue to rise across South America, with our wheels business, especially light vehicle aluminum wheels, continuing to gain share in Mercosur,” stated Pieter Klinkers, President and CEO of Iochpe-Maxion. “To address this growing market and corresponding aluminum wheel demand, Maxion Wheels is implementing three strategic initiatives. First is the utilization of our global operations, together with our domestic forces in Brazil, to support the immediate additional demand. Second is the redeployment of existing global assets to our two Brazilian light vehicle al
GigaDevice Highlights Breakthroughs Across AI, Power, and Consumer Applications at Embedded World 20253.11.2025 17:00:00 CET | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, will present its latest breakthroughs in AI-driven facial and voice recognition, power management, and consumer applications, at this year’s Embedded World North America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103394601/en/ This is the second running of EWNA, with the expo taking place in Anaheim, CA, from the 4th of November. GigaDevice’s technology will be on display at Booth #6085 throughout the three-day exhibition. Like its European sister show, the event brings together many of the leading developers and system architects from across the embedded electronics sector. GigaDevice's demonstrations will highlight the performance and versatility of its GD32 MCU family across several demanding applications: Edge AI Recognition Systems: GigaDevice will showcase facial and voice reco
Coulson Aviation Develops SafeFuel, the First Onboard Fuel Quality Assurance and Protection System3.11.2025 16:30:00 CET | Press release
Coulson Aviation (USA), the world’s largest aerial firefighting company and operator of the most advanced mixed fixed- and rotary-wing firefighting fleet, has developed SafeFuel, the aviation industry’s first onboard system designed to verify fuel quality and detect contamination during refueling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103342390/en/ Coulson SafeFuel is the world’s first patented onboard fuel-quality assurance and protection system. It continuously analyzes the product during refueling, detecting contamination or chemical degradation in real-time, preventing unsafe fuel from ever reaching the tanks. The innovation comes amid growing safety concerns following multiple fuel-related incidents in military and commercial aviation, and recent Navy aircraft accidents under investigation. Coulson Aviation’s aircraft often operate in remote environments around the world, where the risk of contaminated or of
Stefanini Group and Scopism Survey Reveals Rapid AI Adoption, Identifies Key Global Trends Shaping Service Integration and Management (SIAM)3.11.2025 15:42:00 CET | Press release
Launched today at the Scopism Service North Conference in Manchester, UK, the report finds that 85% of organizations now use AI in key SIAM processes, while also highlighting integration and data privacy roadblocks Stefanini Group, a global tech consulting company with strong expertise in digital transformation and artificial intelligence solutions, and Scopism, a global leader in Service Integration and Management (SIAM) best practices, today announced the release of the Global SIAM Survey 2025 White Paper. The eighth annual report, sponsored by Stefanini, was launched and presented by a panel at the Scopism Service North Conference in Manchester, UK, and provides unrivalled insights into SIAM adoption, maturity, and emerging trends worldwide. The survey continues to track the impact of artificial intelligence (AI) on SIAM models. Results show that while reported use of AI in SIAM models overall has remained stable, AI adoption within specific areas, such as incident management, has i
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting3.11.2025 15:31:00 CET | Press release
INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated data in essential thrombocythemia (ET) and translational data demonstrating disease modifying activity in both ET and MF. Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology programs including interim safety data evaluating axatilimab (Niktimvo™) in combination with ruxolitinib in GVHD Incyte to host an investor event and webcast highlighting the mutCALR data from the oral presentation at ASH on Sunday, December 7, 2025, from 11:00 a.m.-12:30 p.m. ET Incyte (Nasdaq:INCY) today announced that data from key programs in its oncology portfolio will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual Meeting, to be held December 6 – 9, 2025, in Orlando. "Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom